Neurofit Participates in Alzheimer's Association International Conference... Introduces Biomarker Analysis Project

AAIC 2022 Neurofit Exhibition Booth. / Photo by Neurofit

[Asia Economy Reporter Jang Hyowon] Neurofit, a specialized company in AI solutions for brain disease imaging, announced on the 3rd that it participated in the 2022 Alzheimer’s Association International Conference (AAIC 2022). At this event, Neurofit introduced the ‘ATNV Project,’ which quantitatively analyzes Alzheimer’s disease biomarkers.

The ATNV Project is a project that quantifies Alzheimer’s disease biomarkers ‘Amyloid (A) - Tau (T) - Neurodegeneration (N) - Vascular neuropathology (V)’ using AI imaging analysis technology to identify the type and stage of dementia. The ATNV Project is expected to be utilized in various fields, including diagnosis of dementia including Alzheimer’s disease, therapeutic intervention, prognosis confirmation, and research on the effects of new dementia drugs. Neurofit plans to establish a global standard for dementia and Alzheimer’s disease diagnosis through this project.

Neurofit focused on introducing the core product groups of the ATNV Project: the brain neurodegeneration imaging analysis software ‘Neurophet AQUA’ and the amyloid/tau quantitative PET imaging analysis software ‘Neurophet SCALE PET.’

Neurophet AQUA is a software medical device that analyzes brain atrophy and white matter degeneration observed in degenerative brain diseases such as Alzheimer’s disease and vascular dementia. With an AI engine, it can segment and analyze brain images in just 5 minutes, reducing the analysis failure rate to 0%. It can be used regardless of race, age, or gender, and provides consistent analysis results across various MRI (magnetic resonance imaging) devices such as GE, Philips, and Canon.

Neurophet SCALE PET is an automatic brain imaging analysis software that quantitatively analyzes Alzheimer’s disease biomarkers by combining PET (positron emission tomography) images and MRI. Based on AI technology, when PET images and MRI are input, it can quantify amyloid beta protein deposition in detailed brain regions within 15 minutes.

Bin Jungil, CEO of Neurofit, said, “At AAIC 2022, we showcased Neurofit’s unique brain imaging analysis technology and products, including the ATNV Project, and received interest and favorable reviews from many participants including multinational pharmaceutical companies. We have continuously discussed specific cooperation plans with leading medical institutions and global healthcare companies, and we expect meaningful collaborations with these companies in the future.”

Meanwhile, the Alzheimer’s Association International Conference (AAIC) is an annual conference where top researchers in the field of dementia science present and discuss the latest research results and theories. This year, it was held simultaneously in San Diego, USA, and online. It started on the 31st of last month local time in San Diego and will continue until the 4th.

This content was produced with the assistance of AI translation services.